Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline Review, H2 2016’, provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

The report reviews pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics and enlists all their major and minor projects

The report assesses Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc.

AkaRx Inc

Amgen Inc.

arGEN-X BV

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Genosco

Hansa Medical AB

Immunomedics, Inc.

Intas Pharmaceuticals Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Novartis AG

Pfizer Inc.

PhytoHealth Corporation

Protalex, Inc.

Rigel Pharmaceuticals, Inc.

Shire Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 9

Therapeutics Development 10

Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Overview 10

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics under Development by Companies 11

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Products under Development by Companies 16

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Companies Involved in Therapeutics Development 18

3SBio Inc. 18

AkaRx Inc 19

Amgen Inc. 20

arGEN-X BV 21

Boehringer Ingelheim GmbH 22

Bristol-Myers Squibb Company 23

Genosco 24

Hansa Medical AB 25

Immunomedics, Inc. 26

Intas Pharmaceuticals Ltd. 27

Jiangsu Hengrui Medicine Co., Ltd. 28

Merck & Co., Inc. 29

Momenta Pharmaceuticals, Inc. 30

Novartis AG 31

Pfizer Inc. 32

PhytoHealth Corporation 33

Protalex, Inc. 34

Rigel Pharmaceuticals, Inc. 35

Shire Plc 36

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Target 38

Assessment by Mechanism of Action 40

Assessment by Route of Administration 42

Assessment by Molecule Type 44

Drug Profiles 46

Antibody for Autoimmune Disorders and Inflammation - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

ARGX-113 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

avatrombopag - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

BI-655064 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

BMS-986004 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

eltrombopag olamine - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

eltrombopag olamine - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

fostamatinib disodium - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

GL-2045 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

GSK-2285921 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Hetrombopag Olamine - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

M-281 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

MK-8723 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

PHN-013 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

PRTX-100 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

romiplostim - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

romiplostim biosimilar - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

SKIO-703 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

SM-101 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

thrombopoietin - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

veltuzumab - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Dormant Projects 94

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Discontinued Products 95

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Product Development Milestones 96

Featured News & Press Releases 96

Jun 10, 2016: Novartis highlights long-term safety data of Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder 96

May 19, 2016: Amgen Highlights Data on Nplate (romiplostim) at 21st Congress Of The European Hematology Association 97

Apr 07, 2016: Novartis receives EU approval for Revolade as first-in-class therapy for children aged 1 year and above with chronic ITP 98

Apr 01, 2016: Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP 99

Jan 29, 2016: CHMP adopts extension to existing therapeutic indication for eltrombopag 100

Jan 28, 2016: Rigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP 100

Jan 07, 2016: Rigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco 101

Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 102

Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 102

Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 103

Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 104

Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 104

Oct 31, 2013: Kyowa Hakko Kirin Announces Launch Of Nplate In Taiwan 105

Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 105

Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 105

Appendix 107

Methodology 107

Coverage 107

Secondary Research 107

Primary Research 107

Expert Panel Validation 107

Contact Us 107

Disclaimer 108

List of Tables

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016 10

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Development by Companies, H2 2016 (Contd..1) 17

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by 3SBio Inc., H2 2016 18

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by AkaRx Inc, H2 2016 19

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Amgen Inc., H2 2016 20

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by arGEN-X BV, H2 2016 21

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 22

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Bristol-Myers Squibb Company, H2 2016 23

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Genosco, H2 2016 24

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Hansa Medical AB, H2 2016 25

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Immunomedics, Inc., H2 2016 26

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Intas Pharmaceuticals Ltd., H2 2016 27

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 28

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Merck & Co., Inc., H2 2016 29

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 30

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Novartis AG, H2 2016 31

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Pfizer Inc., H2 2016 32

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by PhytoHealth Corporation, H2 2016 33

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Protalex, Inc., H2 2016 34

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 35

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Pipeline by Shire Plc, H2 2016 36

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Stage and Target, H2 2016 39

Number of Products by Stage and Mechanism of Action, H2 2016 41

Number of Products by Stage and Route of Administration, H2 2016 43

Number of Products by Stage and Molecule Type, H2 2016 45

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Dormant Projects, H2 2016 94

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Discontinued Products, H2 2016 95

List of Figures

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 37

Number of Products by Targets, H2 2016 38

Number of Products by Stage and Targets, H2 2016 38

Number of Products by Mechanism of Actions, H2 2016 40

Number of Products by Stage and Mechanism of Actions, H2 2016 40

Number of Products by Routes of Administration, H2 2016 42

Number of Products by Stage and Routes of Administration, H2 2016 42

Number of Products by Molecule Types, H2 2016 44

Number of Products by Stage and Molecule Types, H2 2016 44

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports